HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index.

Abstract
The prognostic significance of histopathological grade for postoperative outcome is not yet known for ependymomas. Data on proliferation kinetics of these tumors are few. In our study, the growth fraction was immunohistochemically determined by labelling cell nuclei with the monoclonal antibody Ki-67 in 24 tumors of the ependymoma group (2 malignant ependymomas grade III, 11 ependymomas grade II, 8 spinal ependymomas, and 3 subependymomas). The results were compared with the mitotic index in the same tumor areas. Both growth parameters are related to the grade of malignancy. The differences between the results of spinal ependymomas (grade I) and of intracranial tumors (grade II) were statistically significant. Malignant ependymomas had the highest values. Variable growth potentials could be demonstrated in a few tumors. A non-linear relationship between growth fraction and mitotic index was found, indicating a variable generation time in ependymomas (as in astrocytomas). Thus, with rising grade of malignancy the growth fraction increases and the generation time decreases.
AuthorsR Schröder, C Ploner, R I Ernestus
JournalNeurosurgical review (Neurosurg Rev) Vol. 16 Issue 2 Pg. 145-50 ( 1993) ISSN: 0344-5607 [Print] Germany
PMID8345908 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Ki-67 Antigen
  • Neoplasm Proteins
  • Nuclear Proteins
Topics
  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Antibodies, Monoclonal (immunology)
  • Brain Neoplasms (immunology, pathology)
  • Child
  • Child, Preschool
  • Ependymoma (immunology, pathology)
  • Female
  • Humans
  • Infant
  • Ki-67 Antigen
  • Male
  • Middle Aged
  • Mitotic Index
  • Neoplasm Proteins (immunology)
  • Nuclear Proteins (immunology)
  • Spinal Cord Neoplasms (immunology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: